Analyst Sean Laaman from Morgan Stanley maintained a Buy rating on Halozyme and decreased the price target to $79.00 from $80.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sean Laaman has given his Buy rating due to a combination of factors including Halozyme’s strong royalty revenue performance and disciplined cost management, which are expected to drive earnings per share (EPS) above expectations for the remainder of 2025. The company has already raised its financial guidance twice this year, reflecting confidence in its revenue streams, particularly in royalties.
However, Sean Laaman acknowledges potential risks, such as the uncertainties surrounding the CMS final guidance on drug price negotiations and the proposed acquisition of Elektrofi. While these factors could pose long-term challenges, the current financial outlook and strategic initiatives provide a solid foundation for growth, justifying the Buy rating.
In another report released on October 15, H.C. Wainwright also reiterated a Buy rating on the stock with a $90.00 price target.